RBC Capital Remains Bullish on Biogen (BIIB) with $208 Price Target

Biogen Inc. (NASDAQ:BIIB) is identified as one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. RBC Capital maintains a Buy rating on BIIB with a $208.00 price target. The company reported a 6% year-over-year growth in total revenue to $2.4 billion, with GAAP diluted EPS reaching $1.64. Product revenue also increased by 3% at constant currency. Management is pleased with the transformation in the company’s portfolio, with 45% of total product revenue coming from significant medicines outside of BIIB’s MS business. Biogen Inc. (NASDAQ:BIIB) is a global biopharmaceutical company that focuses on advanced therapies for serious diseases like MS, SMA, Alzheimer’s, and ALS. While BIIB is seen as a potential investment, certain AI stocks may offer greater upside potential with lower downside risk. For more information on undervalued AI stocks, refer to the free report on the best short-term AI stock.

Read more at Yahoo Finance: RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT